Prepare to become a physician, build your knowledge, lead a health care organization, and advance your career with NEJM Group information and services.
Stay connected to what’s important in medical research and clinical practice
Subscribe to the most trusted
and influential source of
medical knowledge
Already a subscriber? Renew or Sign in
Subscribe
or Renew
Selected specialties
View all specialties
Selected Topics
View all topics
Selected Multimedia
View all multimedia
Current Issue
Recent Issues
Browse full issue index
Recently Published Articles
Browse recently published
View all learning/CME
Other NEJM Group Learning
Subscribe
or Renew
This article is available to subscribers. Subscribe now. Already have an account? Sign in
EditorialFree Preview
In January 1922, the management of type 1 diabetes was forever altered when Leonard Thompson became the first person to receive an injection of insulin extract.1 Although treatment with insulin therapy has been possible for more than a century, providers and persons with type 1 diabetes are faced with the grim reality that the attainment of glycemic targets remains elusive for many, increasing the risk of microvascular and macrovascular complications.2 To aid with diabetes management, various technologies have been developed. Some are aimed at measuring glucose, with continuous glucose monitors that currently offer a plethora of data on which to . . .
Select an option below:
Are you a member of an institution such as a university or hospital?
Learn more about Institutional Access
Disclosure forms provided by the author are available with the full text of this editorial at NEJM.org.
From the Department of Pediatrics, Yale School of Medicine, New Haven, CT.
September 29, 2022
N Engl J Med 2022; 387:1228-1229
DOI: 10.1056/NEJMe2210686
Print Subscriber? Activate your online access.
Related Articles
Back to top